Bio-Techne Corp vs Alnylam Pharmaceuticals, Inc.
A head-to-head of Bio-Techne Corp (TECH) and Alnylam Pharmaceuticals, Inc. (ALNY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | TECH | ALNY |
|---|---|---|
| Market Cap | $7.96B | $39.06B |
| P/E (TTM) | 72.84 | 79.22 |
| Forward P/E | 21.42 | 21.24 |
| P/S | 5.72 | 9.77 |
| P/B | 3.77 | 35.98 |
| EV/EBITDA | 18.73 | 44.53 |
| Dividend Yield | 0.63% | — |
| Profit Margin | 9.05% | 13.46% |
| Gross Margin | 64.80% | 81.64% |
| Operating Margin | 19.91% | 13.51% |
| Revenue Growth (YoY) | -1.51% | +96.43% |
| FCF Yield | 3.89% | 1.54% |
| Debt / Equity | 9.59 | 93.86 |
| Current Ratio | 4.49 | 3.13 |
Share:
Compare Bio-Techne Corp with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.